

<b>List of Figures</b>		<b>Page No.</b>
Fig. 1.1	Different natural, pseudo synthetic and synthetic nanocarriers developed in nanomedicine, from the 1970s to nowadays	4
Fig. 1.2	Different copolymer architectures resulting from the copolymerization of two or three different monomers	8
Fig. 1.3	Examples of structures obtained from block copolymers: (i) direct micelles, (ii) vesicles, and (iii) other morphologies: (iiia) inverse micelles, (iiib) lamellar structures, and (iiic) cylindrical or tubular micelles	12
Fig. 1.4	PTX concentration in the plasma (A) and tumor (B) after intravenous injection of NK105 or free PTX to Colon 26-bearing mice	21
Fig. 1.5	Polymeric micelle formation of PEG-PAsp/CDDP (A), and PEG-PGlu/CDDP (B), where carboxylic groups and Pt are linked through coordination bonds. (C) Effect of free CDDP (left-hand side) and PEG-PGlu(CDDP) micelles (right-hand side) on the growth of C26 colon adenocarcinoma subcutaneously transplanted in CDF1 mice	23
Fig. 1.6	Preparation of multifunctional polymeric micelles with tumor selectivity for active drug targeting and pH-sensitivity for intracellular site specific drug transport	25
Fig. 1.7	Drug loading, release, and antitumor activity of degradable polymersomes	30
Fig. 2.1	Sodium Hyaluronan (Repeating disaccharides)	41
Fig. 2.2	Bishydrazide modification of hyaluronan. EDC stands for 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide	42
Fig. 2.3	General structure of poly( $\alpha$ -amino acids) (PAAs)	43
Fig. 2.4	$\text{Cu}^{\text{I}}$ -catalyzed azide-alkyne coupling	43
Fig. 2.5	The alkyne-azide click reaction; [Cu] represents either mononuclear or dinuclear copper (I) complex fragments	44
Fig. 2.6	$^1\text{H-NMR}$ spectrum of PBLG- $\text{N}_3$ in $\text{CDCl}_3 + 15\% \text{TFA}$	46
Fig. 2.7	SEC of Sodium Hyaluronate in acetate buffer at pH 5.6 using pullulan as an internal standard	49
Fig. 2.8	$^1\text{H-NMR}$ Spectrum of Na-Hyaluronate in $\text{D}_2\text{O}$	49

Fig. 2.9	IR spectra of [A] HYACCH [B] acid HYACCH	51
Fig. 2.10	<sup>1</sup> H-NMR Spectrum [A] of HYACCH and [B] acid HYACCH in D <sub>2</sub> O	52
Fig. 2.11	[A] <sup>1</sup> H-NMR spectrum and [B] <sup>13</sup> C NMR spectrum of 1-Azido-3-aminopropane in CDCl <sub>3</sub>	53
Fig. 2.12	IR spectrum of 1-Azido-3-aminopropane	53
Fig. 2.13	IR spectra of PBLG-N3	55
Fig. 2.14	SEC analysis of PBLG-N <sub>3</sub> at 60°C in DMF in the presence of LiBr.	55
Fig. 2.15	Thermal analysis of PBLG-N <sub>3</sub>	56
Fig. 2.16	<sup>1</sup> H-NMR spectra of PBLG- <i>b</i> -HYA in <i>d</i> <sub>6</sub> -DMSO at 60°C	57
Fig. 2.17	IR spectra of (A) mixtures of homopolymers (B) PBLG <sub>23</sub> - <i>b</i> -HYA <sub>10</sub> copolymer	58
Fig. 3.1	Morphology of polymersomes self-assembled from block copolymers	64
Fig. 3.2	(a) DLS autocorrelation function of the PBLG <sub>23</sub> - <i>b</i> -HYA <sub>10</sub> polymersomes and (b) their time relaxation distribution at 90° scattering angle. (Direct dissolution at RT and at 40°C)	71
Fig. 3.3	(a) DLS autocorrelation function of the PBLG <sub>23</sub> - <i>b</i> -HYA <sub>10</sub> polymersomes and (b) their time relaxation distribution at 90° scattering angle. (Nanoprecipitation at 55°C)	72
Fig. 3.4	Berry plot of PBLG <sub>23</sub> - <i>b</i> -HYA <sub>10</sub> in tris buffer solvent at 25°C	73
Fig. 3.5	SANS of PBLG <sub>23</sub> - <i>b</i> -HYA <sub>10</sub> based polymersomes in water	74
Fig. 3.6	Effect of copolymer concentration in DMSO after dialysis	76
Fig. 3.7	Effect of the final concentration of copolymer after dialysis	77
Fig. 3.8	Effect of dilution on preformed polymersomes	77
Fig. 3.9	Effect of pH on the surface potential and hydrodynamic radius of polymersomes obtained by sonication	78
Fig. 3.10	TEM and FF-TEM images of PBLG <sub>23</sub> - <i>b</i> -HYA <sub>10</sub> in tris buffer	79
Fig. 3.11	AFM imaging of PBLG <sub>23</sub> - <i>b</i> -HYA <sub>10</sub> in tris buffer	80
Fig. 3.12	Stability of polymersomes after 90 days	81

Fig. 3.13	Images of polymersomes before and after lyophilization	81
Fig. 3.14	Lyophilization effect	82
Fig. 4.1	Doxorubicin HCl	95
Fig. 4.2	(A) Calibration curve of DOX in tris buffer (pH = 7.4) and in acetate buffer (pH = 5.5), (B) Calibration curve of DOX in DMSO: Tris buffer (80:20)	95
Fig. 4.3	Time dependent stability of DOX in tris buffer (pH = 7.4)	96
Fig. 4.4	DLS of PolyDOX at different feed weight ratios of DOX/copolymer.	97
Fig. 4.5	UV-vis spectra of free DOX, polymersomes before and after loading of DOX at different feed weight ratios of DOX/copolymer	98
Fig. 4.6	Electron microscopy of PolyDOX. (A) TEM and (B) FF-TEM.	99
Fig. 4.7	AFM analysis of PolyDOX	99
Fig. 4.8	Section analysis in AFM image of selected PolyDOX	100
Fig. 4.9	Effect of pH on the zeta potential and hydrodynamic radius of PolyDOX after sonication	100
Fig. 4.10	<i>In vitro</i> release patterns of free DOX and loaded DOX at pH 5.5 and 7.4	102
Fig. 4.11	Higuchi representation of <i>in vitro</i> release profiles of PolyDOX at pH 5.5 and 7.4	102
Fig. 4.12	(A) DLS autocorrelation function (a) of the PolyDOX before (black line) and after reconstitution of lyophilized PolyDOX (light black line) and (b) their time relaxation distribution at 90° scattering angle. (B) Decay rate $\Gamma$ dependency to the square scattering vector $q^2$	104
Fig. 4.13	Phase contrast images of C6 cells after treatment with free DOX and PolyDOX	105
Fig. 4.14	Cell viability (%) at different incubation time with free DOX (17 $\mu$ M) and PolyDOX (17 $\mu$ M)	106
Fig. 4.15	Fluorescence images of C6 glioma tumor cells incubated with free DOX (a and c) and PolyDOX (b and d) incubated for 6h and 24h	108
Fig. 4.16	(a) Cytometry analysis of C6 glioma tumor cells incubated with free DOX and PolyDOX for 6h and 24h. (b) Evolution of the global fluorescence with incubation time for free DOX and	109

PolyDOX

Fig. 5.1	CD44 expression of human breast cancer MCF-7 cells (A) and human U87 glioma cell lines (B) measured by flow cytometry	120
Fig. 5.2	Relative fluorescence intensity of unstained and stained cells (MCF-7 and U87) measured by flow cytometry	120
Fig. 5.3	Fluorescence microscopy images of DOX and PolyDOX uptake in MCF-7 and U87 cells at 3, 6, 24 and 48h incubation times	122
Fig. 5.4	(A) and (B) DOX and PolyDOX uptake in MCF-7 cell at 5 and 10 $\mu$ M DOX concentration respectively. (C) and (D) DOX and PolyDOX uptake in U87 cell at 5 and 10 $\mu$ M DOX concentration respectively	124
Fig. 5.5	(A) and (B) flow-cytometric analysis of DOX (10 $\mu$ M) and PolyDOX (10 $\mu$ M) uptake in presence of free HYA (2mg/mL) in MCF-7 and U87 respectively	125
Fig. 5.6	(A) and (B) flow-cytometric analysis of DOX and PolyDOX uptake and effect of added free HYA (2mg/mL) on uptake of DOX and PolyDOX in MCF-7 and U87 respectively	125
Fig. 5.7	(A) and (B) represent % cell viability of MCF-7 and U87 against PBLG <sub>23</sub> - <i>b</i> -HYA <sub>10</sub> copolymer vesicles respectively	126
Fig. 5.8	(A, B) is the % cell viability with DOX and (C, D) is the % cell viability of PolyDOX incubation in MCF-7 cells at different time points (3-96h). (A and C) represent continuous effect experiment and (B and D) represent delay effect experiment	127
Fig. 5.9	(A, B) is the % cell viability with DOX and (C, D) is the % cell viability with PolyDOX incubation in U87 cells at different time points (3-96h). (A and C) represent continuous effect experiment and (B and D) represent delay effect experiment	128
Fig. 5.10	(A) and (B) ROS level in MCF-7 and U87 respectively compare to their control after treatment with DOX and PolyDOX at 6 and 24h	131
Fig. 5.11	(A) Tumor progression after single administration of free DOX and PolyDOX (5 mg/Kg). (B) Comparative tumor burden after 30 days of PolyDOX and free DOX administration in DMBA breast cancer animals	132
Fig. 5.12	Kaplan-Meier survival curve of tumor bearing rat treated with DOX and PolyDOX at dose 5mg/kg equivalent to DOX	133
Fig. 5.13	(A) Serum creatine kinase levels and (B) lactate dehydrogenase (LDH) levels after DOX and PolyDOX administration in DMBA induced breast cancer animals	133

Fig. 6.1	<sup>99m</sup> Tc Radiolabeling efficiency of DOX, PolyDOX and Blank-POLY	149
Fig. 6.2	Stability of PolyDOX and Blank-POLY in human serum at 37 <sup>0</sup> C for 48h	152
Fig. 6.3	Pharmacokinetic profiles of DOX, PolyDOX, and Blank-POLY after single intravenous injection in rabbit	153
Fig. 6.4	(A) CD44 expression on Ehrlich Ascites Tumor (EAT) cells measured by flow cytometry. (B) Mean fluorescence intensity of unstained and stained cells (EAT) measured by flow cytometry	155
Fig. 6.5	(A) Complete tissue distribution of <sup>99m</sup> Tc-DOX and (B) for <sup>99m</sup> Tc-PolyDOX after intravenous injection in BalB/c mice at a single dose of 5 mg/kg	156
Fig. 6.6	Liver and Heart tissues uptake of <sup>99m</sup> Tc-DOX and <sup>99m</sup> Tc-PolyDOX	156
Fig. 6.7	(A) Liver/Blood uptake ratio and (B) Tumor/Muscle uptake ratio	158
Fig. 6.8	Tumor uptake of DOX and PolyDOX after intravenous injection in BalB/c mice at a single dose of 5 mg/kg	158
Fig. 6.9	Weight changes in healthy BalB/c mice after IV administration of DOX, PolyDOX and Blank-POLY	159
Fig. 6.10	Photo micrograph of heart tissues (A-C) and liver tissues (D-F) after treatment with Saline (A, D), DOX (15mg/kg) (B, E) and PolyDOX (20mg/kg) (C, F)	164
Fig. 6.11	Hemolytic activities of the PolyDOX and Blank-POLY	165
Fig. 6.12	(A) Tumor growth inhibition by single injection of DOX and PolyDOX at 5mg/kg dose in EAT tumor-bearing BalB/c mice. (B) Represent the relative tumor growth after administration of DOX and PolyDOX compared to control	166
Fig. 6.13	Tumor volume doubling time (DT) of EAT tumor bearing mice treated with free DOX and PolyDOX at 5mg/kg equivalent to free DOX	166
Fig. 6.14	(A) Kaplan-Meier survival curve of mice treated with DOX and PolyDOX, (B) % Increase in Life Span (ILS) of mice treated with DOX and PolyDOX compared to control	168
Fig. 6.15	Gamma Scintigraphy of BalB/c mouse bearing Ehrlich Ascites Tumor (EAT) in the right thigh after intravenous administration of 100 $\mu$ Ci <sup>99m</sup> Tc-PolyDOX	169
Fig. 7.1	Docetaxel trihydrate	177

Fig. 7.2	(A) Calibration curve of DOC in tris buffer (pH = 7.4) and in acetate buffer (pH = 5.5), (B) Calibration curve of DOC in ethanol	185
Fig. 7.3	(A) DLS autocorrelation function of the PBLG <sub>23</sub> - <i>b</i> -HYA <sub>10</sub> polymersomes and (B) their time relaxation distribution at 90° scattering angle	186
Fig. 7.4	(A) 50µg/mL of DOC in tris buffer (pH= 7.4). (B) 100µg/mL of DOC loaded PolyDOC	187
Fig. 7.5	FF-TEM of PolyDOC	188
Fig. 7.6	AFM analysis of PolyDOC	188
Fig. 7.7	Section analysis in AFM image of selected PolyDOC	189
Fig. 7.8	Lyophilized PolyDOC	189
Fig. 7.9	<i>In vitro</i> release patterns of free DOC and loaded DOC at pH 5.5 and 7.4	190
Fig. 7.10	Higuchi representation of <i>in vitro</i> release profiles of PolyDOC at pH 5.5 and 7.4	191
Fig. 7.11	A, B and C is the % cell viability with free DOC, and PolyDOC in MCF-7 cells at 24, 48 and 72h respectively	192
Fig. 7.12	A, B and C is the % cell viability with free DOC, and PolyDOC in U87 cells at 24, 48 and 72h respectively	192
Fig. 7.13	<sup>99m</sup> Tc Radiolabeling efficiency of DS and PolyDOC	193
Fig. 7.14	Pharmacokinetic profiles of DS, and PolyDOC after single intravenous injection in rabbit	196
Fig. 7.15	Hemolytic activities of the PolyDOC and DS	197
Fig. 7.16	Tissue distribution of <sup>99m</sup> Tc-DS (A) and (B) for <sup>99m</sup> Tc-PolyDOC after intravenous injection in BalB/c mice at a single dose of 2 mg/kg	198
Fig. 7.17	Tumor uptake of <sup>99m</sup> Tc-DS and <sup>99m</sup> Tc-PolyDOC	199
Fig. 7.18	(A) Liver/Blood uptake ratio and (B) Tumor/Muscle uptake ratio	200